The actions of etazolate (SQ20009) These data suggest that etazolate interacts with the postsynaptic GABA receptor complex at a site distinct from either the GABA recognition site or the benzodiazepine binding site to enhance GABA-mediated inhibition and to increase benzodiazepine binding.
Etazolate (SQ20009) is a compound that has been shown to have anxiolytic-like properties in rats (Beer et al., 1972; Horovitz et al., 1972) and to interact with the GABA receptor complex. In receptor binding studies utilizing membrane preparations of mammalian CNS, low concentrations of etazolate enhance benzodiazepine binding (Supavilai and Karobath, 1979; Williams and Risley, 1979; Leeb-Lundberg et al., 1981) , stimulate Na'-independent GABA binding (Placheta and Karobath, 1980) , and increase the GABA enhancement of benzodiazepine binding (Supavilai and Karobath, 1980; LeebLundberg et al., 1981) . The etazolate enhancement of benzodiazepine binding is Cl-dependent (Supavilai and Karobath, 1979, 1981) and bicuculline (Williams and Risley, 1979; Leeb-Lundberg et al., 1981; Supavilai and Karobath, 1981) and picrotoxinin sensitive (Leeb-Lundberg et al., 1981; Supavilai and Karobath, 1979, 1981) . It has been suggested that the etazolate enhancement of benzodiazepine binding is mediated through the component of the GABA receptor complex identified as the picrotoxinin/barbiturate binding site (Leeb-Lundberg et al., 1981; Olsen, 1981; Ticku and Davis, 1982) .
In order to understand the physiological actions of etazolate more completely, we have investigated its effects on the electrophysiological characteristics of neurons in primary cultures of rat cerebral cortex and its ability to modify GABA-mediated inhibition in these cells. In addition, we have evaluated the effects of etazolate on benzodiazepine binding and on the GABA stimulation of benzodiazepine binding in the same culture system. The use of cortical cultures has allowed us to study the actions of this drug on a living preparation by both physiological and biochemical methods. The dose response relationships and pharmacological specificities identified from the results of the physiological and biochemical studies are similar. These data indicate that etazolate increases GABA-mediated inhibition by prolonging the duration of IPSPs and suggest that etazolate interacts with a component of the GABA receptor complex which is distinct from either the GABA recognition site or the benzodiazepine binding site.
Materials and Methods
Tissue culture.
Primary cultures of rat cerebral cortex were produced according to previously reported methods 762 The Journal of Neuroscience Etazolate Actions in Cultured Cortical Neurons 763 (Dichter, 1978; Snodgrass et al., 1980; White et al., 1981) . Cerebral cortices were removed from fetal rats (l&day gestation) and were dissociated by mincing, trypsinization, and trituration. The dissociated cortical cells were plated onto either collagen-polylysine-coated coverslips maintained in 35mm plastic dishes (for electrophysiology, 3.5 X lo5 cells/dish) or into trays of similarly coated 16-mm wells (for biochemistry, 1 X lo5 cells/well). The culture medium was Eagle's Minimal Essential Medium supplemented with 5% rat serum, 100 mg% glucose, penicillin (20 units/ml), and streptomycin (20 pg/ml). The cells were kept in a 5% COz incubator at 37"C, and the medium was changed three times per week. At confluence of non-neuronal cells, further mitosis was inhibited by the addition of lop7 M cytosine arabinoside for 24 hr. Electrophysiological and biochemical assays were performed on cells after 3 to 7 weeks in culture.
Electrophysiology.
Electrophysiological
methods have been reported previously (Dichter, 1978 (Dichter, , 1980 . Coverslips containing cortical neurons were placed into 35-mm dishes containing a physiological salt solution (151 mM Na+, 3 mM Kf, 154 mM Cl-, 1.8 mM Ca2+, 1 mM Mg'+, buffered with 2 mM phosphate to pH 7.2 to 7.3) and were maintained at 35" to 37°C. Individual neurons were visualized with an inverted phase microscope (Zeiss) at X 200 magnification and were impaled with 3.5 M KAcfilled glass microelectrodes (35 to 85 megohms). The compounds under study were applied by pressure ejection from microelectrodes with tips broken to a diameter of approximately 10 pm (Choi, 1978) . In general, three drug-filled miniperfusion pipettes were positioned near the impaled cell. Cell responses were analyzed from strip chart recordings and from photographed records of oscilloscope traces. Membrane input resistance was calculated by applying Ohm's law to the voltage changes which resulted from the injection of 50-msec hyperpolarizing constant current pulses (0.2 to 1.0 nA). Cells accepted for data analysis had resting membrane potentials of -40 mV or greater, initial input resistances of 30 to 100 megohms, and action potentials of 50 mV or greater.
Receptor binding studies. The methods employed for the binding studies were similar to those described previously (White et al., 1981) . Cultures were washed three times with 1 ml of HEPES-buffered physiological salt solution (White et al., 1981) at room tern B erature, -23°C and were incubated for 15 min in 1 nM [ Hlflunitrazepam and any other drug under study. Nonspecific binding was determined in parallel incubations containing 1 pM clonazepam, a ligand which blocks binding to neuronal benzodiazepine receptors, and accounted for about 25% of the total binding. The incubation was terminated by two rapid (less than 8 set total) washes in HEPES buffer. In studies employing Cl--free media, all of the chloride was replaced by acetate. At the conclusion of the incubation and washes, the cultures were solubilized in 0.1 N NaOH. The amount of radioactivity in each sample was determined by liquid scintillation spectrometry using a Triton/toluene/Omnifluor liquid scintillation cocktail. All studies were performed in at least triplicate, and each study was replicated at least four times with cultures prepared from different dissections. Etazolate, at all concentrations tested (0.3 to 100 PM), produced a large increase in the duration, but not the amplitude, of IPSPs (Fig. 1, A and B) . The duration of IPSPs was measured as the time from onset to half-recovery (IPSP t&. The IPSP tl12 values for control IPSPs varied from 10 to 25 msec and showed no consistent relationship to IPSP amplitudes (Fig. 1C) It has been shown previously that the IPSPs in these cultures are GABA mediated and that virtually all the neurons are GABA sensitive (Dichter, 1980) , findings which are in agreement with reports of in situ cortical sensitivity to GABA (for reviews see Krnjevic, 1974, and Curtis and Johnston, 1974) . We tested the hypothesis that the effects of etazolate on IPSP duration were due to an interaction with the GABA receptor complex by examining the effects of etazolate on the response to exogenously applied GABA. The responses of a typical cell to the application of GABA alone, etazolate alone, and GABA + etazolate are shown in Figure 2 (see insert). The application of GABA (5 PM) produced a moderate increase in membrane conductance, whereas etazolate (3 PM) applied alone produced no conductance increase. When 3 pM etazolate + 5 ,uM GABA were applied, the increase in membrane conductance was -3.5 times greater than that mediated by GABA alone. The etazolate-induced potentiation of the response to exogenously applied GABA suggests that this action of etazolate is mediated postsynaptically.
The dose response relationship for the etazolate potentiation of GABA-mediated conductance increases is shown in Figure 2 . Low concentrations of etazolate (tl PM) produced no change in membrane conductance when applied alone and did not affect the GABA-mediated increase in membrane conductance. High concentrations of etazolate (10 to 100 pM) caused membrane hyperpolarization and increased conductance. Etazolate (3 to 100 PM) + GABA produced an increase in membrane conductance which was greater than the sum of the conductance changes due to etazolate and GABA alone. Thus, etazolate potentiated the response to exogenously applied GABA over a wide concentration range. The etazolate-mediated changes in membrane conductance for these studies were measured at the time point during the first 10 set of drug perfusion which corresponded to 764 Barnes et al. Vol. 3, No. 4, Apr. 1983 CONT VFF ' The responses of these neurons to the application of etazolate alone are included in the data shown in Figure 3 . Insert, Response of a typical cell to 5 pM GABA, 3 pM etazolate, and 5 ELM GABA + 3 pM etazolate. Bars over the traces represent the times during which drugs were applied. The following changes in membrane potential (mV) and in membrane conductance (nS) were observed: control = -44 mV, 22 nS; +GABA = -56 mV, 40 nS; +ETAZ = -47 mV, 20 nS; +GABA + ETAZ = -60 mV, 62 nS. (The membrane hyperpoiarization occurring with etazolate application is not associated with a conductance increase and is probably an artifact of microperfusion.) the maximal response to GABA + etazolate (see arrows in Fig. 2 insert) .
Direct membrane effects of etazolate. The direct membrane effects of etazolate (3 to 100 pM) in neurons with incoming synaptic activity are summarized in Figure 3 . Concentrations of etazolate greater than 3 PM produced a hyperpolarization which was maximal during the first 10 set of drug perfusion (see insert, Fig. 3, point A) and a conductance change which continued for many seconds and was often maximal after etazolate perfusion had been terminated (see insert, Fig. 3, point B) . The increases in membrane conductance were measured at the points of maximum drug effect and are summarized in Figure 3 . Thirty micromolar etazolate produced maximal conductance increases, and the response diminished with 100 pM etazolate.
Etazolate produced direct membrane effects (hyperpolarization and conductance increase) which were qualitatively similar to those induced by GABA. It has been shown previously that GABA increases Cl-permeability in cultured cortical neurons (Dichter, 1980 which caused maximal effects. KC1 electrodes allowed chloride ions to leak into the impaled cell and dramatically altered the Cl-equilibrium potential. When etazolate and GABA were applied alternately to a small group of neurons in which the internal chloride ion concentration had been changed, the membrane potentials produced by each compound showed a close correlation (Fig. 4) . Therefore, it seemed likely that etazolate, like GABA, produced an increase in membrane permeability to Cl-.
Effects of etazolate under conditions of reduced synaptic activity. As indicated above, etazolate potentiated the responses to exogenously applied GABA, and GABA and etazolate produced similar membrane effects. These data suggest that the direct effects of etazolate might result from an enhancement of the actions of endogenous GABA released into the culture medium. We investigated this possibility by blocking neuronal activity with tetrodotoxin (TTX) to decrease the spontaneous release of GABA. Etazolate (3 to 100 PM) applied alone to TTXtreated cells produced smaller conductance increases than those observed under control conditions (Fig. 3) . In addition, in TTX-treated cells, there was a trend toward a continued increase in membrane conductance at 100 PM etazolate. These data suggest that reducing the amount of "endogenous" GABA decreased the etazolate response, an indication that at least some of the direct membrane effects of etazolate might be due to the potentiation of endogenous GABA.
It also seemed likely that endogenous GABA affected the degree to which etazolate potentiated the conductance increase mediated by exogenously applied GABA. In order to evaluate this possibility, we applied etazolate + GABA to TTX-treated neurons and to cells bathed in 0 mM Ca", 10 mM Mg2+ media. Under these conditions of reduced synaptic activity, etazolate (3 to 100 PM) greatly potentiated GABA responses, and the maximum enhancement occurred with 30 pM etazolate (Fig. 5) . The combined GABA + etazolate responses were much greater in both TTX-treated cells and in cells bathed in low Ca2+, high Mg2+ than in cells assayed under normal recording conditions (Fig. 2) . These data suggest that, in addition to its effects on the "direct" response of etazolate, endogenous GABA may reduce the etazolate potentiation of responses to exogenously applied GABA. However, the mechanism by which this occurs is not clear.
Physiological interactions of etazolate with diazepam. Diazepam has been shown previously to increase IPSP amplitude and to enhance GABA-mediated conductance but to have no effect on conductance when applied alone (White et al., 1981) . In order to study the physiological interactions of diazepam and etazolate, we examined the effects of each drug and of both together on spontaneously occurring IPSPs and on the conductance increases mediated by exogenously applied GABA. We chose a concentration of etazolate (3 PM) which prolonged the duration of IPSPs, potentiated the GABAmediated increase in membrane conductance (Fig. 2) , and did not change Cl-conductance when applied alone (Fig. 3) . The effects of 3 PM etazolate and 100 nM diazepam on IPSPs are illustrated in Figure 6A . Diazepam increased the amplitude but not the duration of inhibitory potentials, and etazolate increased the duration but not the amplitude. When etazolate and diazepam were applied together, both the amplitude and the duration of IPSPs were enhanced. There was no change in membrane conductance when either drug was applied alone nor when the two compounds were applied together.
The effects of etazolate and diazepam on the response to exogenously applied GABA are shown in Figure 6B . When etazolate + diazepam + GABA were applied, the enhancement of the GABA-mediated increase in Clconductance was greater (average of 50 to 60% greater in seven cells) than the sum of the individual drug potentiations. Etazolate and diazepam seemed to interact with the GABA receptor complex in different ways, because the two drugs had different effects on IPSPs and were synergistic in their enhancement of GABA-mediated increases in Cl-conductance. The responses of these neurons to the application of etazolate alone are included in the data shown in Figure 3 and are not significantly different from the data given in that figure.
agents which interact with the GABA receptor complex. Picrotoxinin is a noncompetitive antagonist which blocks the GABA-mediated increase in Cl-conductance (Takeuchi and Takeuchi, 1969; for review see Obata, 1977) but acts at a site distinct from the GABA recognition site (Olsen et al., 1978) ; bicuculline is a competitive antagonist of the GABA recognition site (Johnston et al., 1972; Simmonds, 1980;  for review see Andrews and Johnston, 1979) . In our system, both 50 PM picrotoxinin (Fig. 7A ) and 50 PM bicuculline (Fig. 7B) blocked the etazolatemediated membrane hyperpolarization and conductance increase which occurred during drug application. Interestingly, the maximum conductance increase produced by etazolate which typically occurred after the termination of drug perfusion was antagonized more by picrotoxonin than by bicuculline (indicated by arrows in Fig. 7 ). These data demonstrate that the actions of etazolate are sensitive to both picrotoxinin and bicuculline and suggest that there may be some differences in the interaction of these two GABA antagonists with etazolate. Both GABA and glycine (Barker and Ransom, 1978; Barker and McBurney, 1979a; Dichter, 1980) have been shown to increase Cl-conductance in cultured neurons. In order to test whether etazolate was specific for GABA receptor-associated Cl-channels, we applied etazolate together with glycine in the same experimental paradigm used for GABA. No increase in the glycine response was observed (n = 5 cells), indicating that the etazolate enhancement of Cl-conductance was due to a specific interaction with the GABA receptor complex.
Etazolate has been shown to be a phosphodiesterase (PDE) inhibitor in neuronal and non-neuronal systems (Beer et al., 1972; Mansour and Mansour, 1979) , as is SQ20006 (Chasin et al., 1977) , a structurally related compound which has no anti-anxiety activity. The effects of 10 pM and 100 pM SQ20006 on IPSPs and on GABAmediated responses were examined (n = 14 cells). There was no increase in the duration of IPSPs when SQ20006 was applied alone, nor did this drug produce an increase in membrane conductance. The application of SQ20006 together with 5 PM GABA did not result in any stimulation of GABA-mediated effects. These data suggest that the physiological effects of etazolate are probably not due to its activity as a PDE inhibitor.
Receptor binding studies The binding of [3H]flunitrazepam
to the neuronal-type benzodiazepine binding site has been investigated extensively on living cultures of rat cerebral cortex (White et al., 1981) . These studies demonstrated numerous interactions between the binding of [3H]flunitrazepam and known components of the GABA receptor complex including the GABA recognition site, the picrotoxinin recognition site, and the Cl-ionophore. It has also been shown that GABA increases ["Hlflunitrazepam binding with a dose response relationship which is similar to that observed for the physiological action of GABA (White et al., 1981) . These results suggest that changes in benzodiazepine binding can be used to monitor interactions of a compound with the GABA receptor complex. In the present experiments we measured the binding of [3H] Figure 8 . Etazolate, at concentrations between 1 and 10 PM, produced a dose-dependent increase in the binding of [3H] flunitrazepam to 124 +-7% of control. At higher concentrations this effect was reversed, and by 100 PM there was a decrease in binding to 88 f 7% of control. This inverted U-shaped dose response relationship was similar to that reported above for the physiological actions of this drug (Figs. 2, 3 , and 5), although binding with a dose response relationship similar to that observed previously (White et al., 1981) . Etazolate shifted the dose response curve for GABA to the left, indicating that it increased the efficacy with which GABA enhanced [3H]flunitrazepam binding. The presence of etazolate also caused a reversal in the enhancement of binding with higher concentrations of GABA (>lO PM). This reversal in the action of GABA was not seen in the absence of etazolate even at very high GABA concentrations (to 5 1~1~) tested previously (White et al., 1981) . These results suggest an interesting interaction between GABA and etazolate. Either GABA (>lO pM) shifted the etazolate-induced decrease in benzodiazepine binding to lower concentrations of etazolate, or etazolate modified the action of high concentrations of GABA to produce a decrease in binding. The former explanation seems to be more likely, but it is difficult to distinguish between these possibilities given our current understanding of the GABA receptor complex. In either case, the data indicate that, at low concentrations, GABA and etazolate affect different but interacting sites to increase the binding of r3H]flunitrazepam to cortical neurons.
Pharmacological sensitivities of etazolate interactions with the GABA receptor complex. Ligands for the other components of the GABA receptor complex modify the binding of [3H] flunitrazepam to cultured neurons (White et al., 1981) . In the absence of exogenous GABA, bicuculline slightly depresses the binding of [3H]flunitrazepam and picrotoxinin has no effect; both antagonists block the GABA-mediated enhancement of ["Hlflunitrazepam binding. The replacement of Cl-in the incubation media with acetate enhances [3H]flunitrazepam binding and blocks the ability of GABA to enhance [3H]flunitrazepam binding. In the studies reported here, we investigated the ability of etazolate to modify these interactions among the different components of the postsynaptic GABA receptor complex.
In the present studies, both bicuculline methiodide (100 PM) and picrotoxinin (100 PM) blocked the etazolate (10 PM) enhancement of [3H]flunitrazepam binding (Table I ). The replacement of chloride in the media by the impermeable anion acetate also blocked the etazolate enhancement of benzodiazepine binding (Table I ). These results demonstrate that many of the ligands known to interact with the GABA receptor complex modified the actions of etazolate on benzodiazepine binding; GABA increased the enhancement, and the enhancement was blocked by bicuculline, picrotoxinin, and acetate. 
